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PRETREATMENT WITH IMATINIB MESYLATE INCREASES TRANSPLANT-
RELATED MORTALITY AFTER ALLOGENEIC TRANSPLANTATION
Zander, A.R.; Zabelina, T.; Renges, H.; Schieder, H.; Fehse, N. Uni-
versity Hamburg-Eppendorf, Hamburg, Hamburg, Germany.
Imatinib mesylate (IM) has excellent activity against chronic
myelogenous leukemia and Philadelphia-positive acute lympho-
blastic leukemia and is presently the preferred front-line treatment
for CML. Because of the effectiveness of IM, most patients will
receive an allogeneic bone marrow transplantation after failure
from IM. There is concern based on case reports that pretreatment
with IM might predispose to toxicity after transplantation. We
undertook a retrospective study of 23 patients who reveived IM
before transplantation and 23 historical controls without IM treat-
ment. There was a trend toward a higher incidence of acute
graft-versus-host disease (GvHD) II to IV in the IM group (P 
.07) and a signiﬁcantly higher incidence of severe GvHD III to IV
in the IM group (57% vs 17%; P  .006). The mean maximun
bilirubin was 5.4 in the IM group and 3.3 in the non-IM group.
Overall survival (OS) was 16% in the IM group and 48% in the
non-IM group (P  .03). Transplantation-related mortality
(TRM) was 74% in the IM group and 40% in the non-IM group
(P  .07). Discontinuation of IM at least 15 days before transplan-
tation decreased the TRM (P  .05) and led to a trend toward
improved OS (P  .09). Patients treated with IM suffered more
TRM, GvHD, and liver toxicity and had a poorer survival than
those who were not. Discontinuation of IM 2 weeks before trans-
plantation might decrease TRM. Larger studies are needed to
evalutate IM as a risk factor for a consecutive transplantation.
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CELLULAR IMMUNOTHERAPY UTILIZING LOW-DOSE IRRADIATION,
BONE MARROW TRANSPLANTATION. AND DONOR LYMPHOCYTE IN-
FUSIONS FOR ACUTE LEUKEMIA: A PHASE II STUDY
Colvin, G.A.1; Rathore, R.1; Lum, L.G.1; Abedi, M.1; Ballen, K.K.2;
Dey, B.R.2; Elfenbein, G.J.1; Quesenberry, P.J.1 1. Roger Williams
Medical Center, Adele R. Decof Cancer Center, Providence, RI; 2.
Massachusetts General Hospital, Boston, MA.
We previously studied allogeneic bone marrow transplantation
(BMT) with HLA-identical donors using 100 cGy as host condi-
tioning and infusing 1  108 CD3 cells/kg from nonmobilized
peripheral blood and achieved complete responses (CRs) in 4 of 11
refractory hematologic malignancy patients. Only 25% of those
eligible for allogeneic BMT have an HLA-identical sibling donor;
nearly 100% have HLA-3/6 or HLA-4/6 donors. We evaluated
CD3 cell dose escalation with transplantation in patients with
refractory malignancies. We performed a total of 44 HLA-mis-
matched transplants with escalation of the CD3 cell dose from
1  106 to 2  108 cells/kg using G-CSF primed PBSC, with a
conditioning regimen of 100 cGy TBI. Thirty patients have been
treated at the highest dose level. The CD34 cell dose averaged
2  106 cells/kg. Patient age ranged from 16 to 82 years. One
treatment-related death occurred from grade IV acute graft-ver-
sus-host disease. Most patients had a transient infusional haploim-
munostorm syndrome believed to be cytokine/immunologically
modulated. There were no objective responses in the 15 patients
with solid tumors. Of the 29 patients with hematologic malignan-
cies, 3 of 5 patients with NHL responded to treatment. Two
patients remain in CR and 29 and 37 months, and 1 patient is
in partial response (PR) with marrow-only disease at 34 months.
We observed several encouraging responses in patients with re-
fractory AML. We treated 15 patients with AML and have ob-
tained a durable CR in 3 of 12 and transient PR in 7 of 12 evaluable
patients. All responses occurred at CD3 levels of 1 to 2  108
cells/kg. CR occurred even after the loss of detectable donor
chimerism ( 5%). Donor cells labeled with indium111 analyzed 1,
2, 3, and 6 days after BMT in 1 patient showed persistent signal in
the bone marrow and spleen. Serial bone marrow biopsies per-
formed in several patients showed evidence of large tumor reduc-
tion and early resumption of hematopoiesis. The kinetics of donor
chimerism from patients show a majority of donors cells in
circulation3marrow at 24 hours and marrow3circulation at 48
hours. There was a loss of detectable chimerism by 6 days. In
summary, TBI of 100 cGy followed by HLA-mismatched trans-
plantation is a biologically active therapy for refractory AML and
NHL. This well-tolerated outpatient treatment produced minimal
toxicity for the majority of patients. Theories on biological effect
include an initial graft versus tumor cell kill, altered host immune
response breaking host tumor tolerance, persistent nondetectable
microchimerism, and any combination of these 3 mechanisms.
AUTOLOGOUS
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RITUXIMAB DOES NOT INHIBIT CHEMO-MOBILIZATION OF HPC OR
ENGRAFTMENT FOLLOWING AUTOLOGOUS TRANSPLANT FOR LYM-
PHOMA
Kaufman, J.L.; Lonial, S.; Hicks, M.; Langston, A.; Flowers, C.;
Lechowicz, M.J.; Khoury, H.; Waller, E.K. Winship Cancer Institute,
Emory University School of Medicine, Atlanta, GA.
Treatment for patients with relapsed non-Hodgkin’s lymphoma
(NHL) and Hodgkin’s lymphoma (HL) includes high-dose che-
motherapy and autologous hematopoietic progenitor cell (HPC)
transplant, but the role of rituximab (R) during mobilization of
autologous HPC is unknown. The addition of R may purge the
HPC graft of B cells but may impact negatively on mobilization or
engraftment. Methods: We performed a single institution IRB-
approved review of the effect R in the mobilization regimen in 80
patients with relapsed/refractory HL or NHL who underwent
chemomobilization of HPC followed by autologous transplant.
The study group included 32 patients with relapsed HL, 6 of who
had LPHL and expressed CD20 on their lymphoma cells, and 48
patients with relapsed or refractory NHL, of whom 32 had
CD20 lymphoma. Patients received chemotherapy with or with-
out R. Chemotherapy consisted of ICE (n  46, 25 with R),
HyperCVAD (n  14, 8 with R), single-agent cytoxan (n  9, 2
with R), VTEPA (n  4, 1 plus R), CHOP (n  3, 1 plus R), and
others (n  4, 1 with R). The conditioning regimens before
transplantation were Bu/CY/VP16 for 92% of patients in the R
group and 93% of those in the no R (NR) group. The content of
CD34 cells in the apheresis product was measured by ﬂow
cytometry using the ISHAGE method, and engraftment was re-
corded based on IBMTR criteria. Results: The average number
( SD) of CD34 cells collected in the entire study was 9.2 
106/kg  1.36 in a median of 2 days of apheresis. There were no
differences in the content of CD34 cells collected in patients who
received R (9.9  1.5  106 CD34 cells/kg) versus NR (9  1 
106 CD34 cells/kg), and no differences in the CD34 cells
collected from HL (10.6  11  106 CD34 cells/kg ) versus
NHL patients (8.6  13  106 CD34 cells/kg). Two patients in
the NR arm required 2 mobilizations versus none in the R arm.
Neutrophil engraftment was equal between the R and NR groups
with median 13 days versus 12 days, respectively, as was platelet
engraftment (median, R  19 days vs NR  22 days). With a
medium follow-up of 1 year, there is no difference in survival in
patients treated with (91%) or without R (88%). Conclusion:
Rituximab during the mobilization regimen did not have adverse
effects on HPC collection, neutrophil or platelet engraftment after
autologous transplantation in patients with relapsed/refractory HL
or NHL. The effect of including rituximab during HPC mobili-
zation on event-free survival in autologous HPCT warrants eval-
uation in phase 3 trials.
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PEGFILGRASTIM ALONE SUCCESSFULLY MOBILIZES PERIPHERAL
CD34 CELLS IN CHEMOTHERAPY NAIVE SUBJECTS WITH SOLID
TUMORS: INITIAL RESULTS OF A PHASE 1–2 STUDY
Pettengell, R.1, Willis, F.1, Woll, P.J.2 4, Desborough, C.3, Buchanan,
K.3 1. Department of Haematology, St. George’s Hospital Medical
School, London, United Kingdom; 2. Cancer Research Centre, Weston
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Park Hospital, Shefﬁeld, United Kingdom; 3. Amgen Ltd., Cambridge,
United Kingdom; 4. Nottingham City Hospital, Nottingham, United
Kingdom.
Classic strategies for peripheral blood progenitor cell (PBPC)
mobilization include daily administration of a growth factor, such
as ﬁlgrastim, alone or with marrow suppressive chemotherapy. A
single injection of pegﬁlgrastim has been shown to be comparable
to daily injections of ﬁlgrastim in the treatment of chemotherapy-
induced neutropenia. One of the objectives of this phase 1–2 study
was to provide dose-ﬁnding information regarding the efﬁcacy and
kinetics of cytokine-alone PBPC mobilization with pegﬁlgrastim.
Methods: Chemotherapy-naive subjects with a variety of solid
tumors were randomized to receive a single administration of 6, 12,
or 18 mg of pegﬁlgrastim on day 1 or daily administration of 10
g/kg ﬁlgrastim from day 1 until day 7. Daily blood samples for
peripheral CD34 analysis were collected on days 1–7 and then on
days 9 and 12. No chemotherapy was administered during this
cycle. For each subject, peak CD34 cell count was deﬁned as the
maximum cell count observed between days 3 to 7, inclusive.
Results: Of 61 subjects randomized into the study, all received
study drug (15 subjects each in the pegﬁlgrastim 12 mg and 18 mg
and ﬁlgrastim groups and 16 subjects in the pegﬁlgrastim 6 mg
group). The treatment groups were balanced in terms of demo-
graphics and baseline characteristics. The most common tumor
types were non-small cell lung cancer (n  23 [38%]) and ovarian
(n  19 [31%]). The mean peak CD34 cell count was similar in
the ﬁlgrastim and pegﬁlgrastim 6mg groups (4.51 and 4.24 
104/ml, respectively), whereas the pegﬁlgrastim 12 mg and 18 mg
groups had higher mean peaks (8.18 and 9.96  104/ml, respec-
tively). Pegﬁlgrastim 12 mg and 18 mg mobilized signiﬁcantly
more peripheral CD34 cells than ﬁlgrastim (P  .034 and .006,
respectively). The subject incidence of SAEs was low and compa-
rable between groups. Conclusion: In chemotherapy-naive sub-
jects with solid tumor, single-day administration of pegﬁlgrastim is
at least as efﬁcacious as repeated daily injections of ﬁlgrastim (10
g/kg) in its ability to successfully mobilize peripheral CD34
cells. A dose-response relationship of CD34 mobilization is ob-
served. Pegﬁlgrastim 12 mg and 18 mg mobilize higher numbers of
CD34 cells than does daily administration of ﬁlgrastim. Pegﬁl-
grastim at 6 mg, 12 mg, and 18 mg is generally safe and well
tolerated in this setting. The trial is ongoing, and updated results
on safety and efﬁcacy will be presented.
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INTERIM ANALYSIS OF A PHASE II STUDY OF RISK-ADAPTED INTRA-
VENOUS MELPHALAN FOLLOWED BY ADJUVANT DEXAMETHASONE
(D) AND THALIDOMIDE (T) FOR NEWLY DIAGNOSED PATIENTS WITH
SYSTEMIC AL AMYLOIDOSIS (AL)
Cohen, A.D.; Zhou, P.; Reich, L.; Fircanis, S.; Drake, L.; Hedvat, C.;
Teruya-Feldstein, J.; Filippa, D.A.; Fleisher, M.; Comenzo, R.L.
Memorial Sloan-Kettering Cancer Center, New York, NY.
High-dose melphalan (M) with autologous stem cell transplant
(ASCT) is effective therapy for AL, but treatment-related mortal-
ity (TRM) remains high, and hematologic complete responses
(CR) occur in a minority of patients. In this study, we investigated
whether a risk-adapted approach to intravenous (IV) M dosing
could decrease TRM, and whether adjuvant D 	 T could improve
hematologic and amyloid-involved organ response rates. Low-risk
patients (1 or 2 major organs involved, no advanced cardiac disease)
receive M 100, 140, or 200 mg/m2 with ASCT based on age,
cardiac involvement, and renal function. High-risk patients (3
organs involved or advanced cardiac disease) receive 2 cycles of M
40 mg/m2 without ASCT. Patients with persistent clonal plasma
cell disease at 3 months receive 9 months of adjuvant DT or D
alone (if history of deep venous thrombosis or neuropathy). Since
September 2002, 39 patients (median age, 58 years; range, 34–73
years; 67% male) have enrolled for a median of 1.5 months (range,
0.5–7 months) from diagnosis. Organ involvement includes 13
(33%) cardiac, 25 (64%) renal (13 with renal only), 13 (33%)
liver/GI tract, and 10 (26%) peripheral nervous system. Only 4
high-risk patients have enrolled; all had symptomatic cardiac in-
volvement and died a median of 4 months (range, 2.5–6 months)
after M. Thirty-four patients in the low-risk group have been
treated, and TRM is 6.4% (2/31), with an additional 3 patients
alive 100 days posttreatment. Four low-risk patients have died of
progressive disease (PD) a median of 11.7 months (range, 7–18
months) after M. At 3 months, 19/30 (63%) evaluable low-risk
patients had hematologic responses (5 CR, 14 PR) and 11 had
stable disease. Twenty patients with persistent clonal disease began
adjuvant therapy with D 	 T. At 12 months, 11/15 (73%) evalu-
able patients had responses (5 CR, 6 PR) and 8 (67%) had objective
improvement in amyloid-related organ function. Preliminary anal-
ysis of serum free light chain data (n  31) shows an association
between a persistently abnormal 
: ratio 3 months after treatment
and an increased risk of death (relative risk 1.54; 95% conﬁdence
interval  1.12–2.12; P  .02). Analyses of the prognostic signif-
icance of serial troponin and BNP levels and plasma cell cyclin D1
expression are ongoing. In conclusion, risk-adapted dosing of IVM
in newly diagnosed AL patients has a low TRM. Adjuvant D 	 T
is feasible, has moderate toxicity, and has to date beneﬁted 20%
(4/20) of patients with persistent clonal plasma cell disease 3
months post-ASCT.
Adjuvant Therapy* (n  25 Eligible)
Thal/Dex (n) Dex (n)
Began therapy (n  5
refused or too ill) 12 8
Completed 9 mos. 4 3
Still on (<9 mos.) 3 2
Reasons for
discontinuation
PD (n  2),
pulmonary embolus
(1), avascular
necrosis hip (1),
RSV pneumonia (1)
PD (n  2),
intolerance (1)
Benefit to
hematologic
response
SD (@3 mos.)3PR
(@12 mos.) (n 
1), PR3CR (n  1)
SD3PR (n  1),
PR3CR (n 
1)
*Dexamethasone (1 to 3 four-day pulses monthly); Thalidomide
(50–200mg nightly)
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IDENTIFICATION AND TISSUE DISTRIBUTION OF ANTIGEN-SPECIFIC
RECIPIENT ANTI-DONOR CD8 T CELLS THAT RESIST HEMATOPIETIC
ENGRAFTMENT FOLLOWING MHC-MATCHED ALLOGENEIC PROGENI-
TOR CELL TRANSPLANTS
Shatry, A.M.; Levy, R.B. University of Miami Medical School, Miami,
FL.
The role of natural killer (NK) cells in resistance to progenitor
cell (PC) engraftment has been extensively studied in experimental
bone marrow transplantation (BMT). Although antigen-speciﬁc T
cells are believed to be the principal effectors resisting engraftment
following clinical hematopietic cell transplants (HCT), less is
known involving the biology and distribution of these cells follow-
ing experimental HCT. The present studies established a model of
resistance using the well-deﬁned dominant, that is H60 MiHA (in
B6 mice primed to BALB.B; B6BALB.B) to precisely identify and
track host T cells following BMT into recipients sensitized against
donor transplant antigens. We utilized an H60/Kb tetramer and
determined the mean (12.2% 	 0.88 of CD8 cells) frequency of
circulating CD8 H60-speciﬁc T cells (5.6%–20.5%) in B6 re-
cipients before BMT. Most ( 90%) CD8H60 cells expressed
the memory phenotype (CD44, Ly6C, CD25/CD69). Inter-
estingly, the frequency of CD8 H60 T cells was higher in the
bone marrow than in the blood and splenic compartments, sug-
Oral Presentations
7BB&MT
